Balyasny Asset Management
ZVRA icon

Balyasny Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Balyasny Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,980
Closed -$266K – 3631
2025
Q3 		$266K Buy
+27,980
New +$281K ﹤0.01% 2624

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Balyasny Asset Management's ZVRA Position: Q4 2025 in Review

Balyasny Asset Management sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 27,980 shares — an estimated $266K sold.

Balyasny Asset Management first reported a position in ZVRA in Q3 2025 and held it in 1 quarter. The position peaked at $266K in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Balyasny Asset Management reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 27,980 Zevra Therapeutics shares in Q4 2025, an estimated $266K.
  • Balyasny Asset Management first reported a position in Zevra Therapeutics in Q3 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Zevra Therapeutics position peaked at $266K in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.